Carbapenem Resistant Gene of Pseudomonas Aeruginosa

Determining the frequency of classifying VIM, IMP and NDM


Methods:
The isolates of P. aeruginosa were isolated from sputum, blood, pus, fluid from patients (non-duplicate samples) in different clinical departments. They had been identified and performed antibiotic susceptibility testing by using Vitek 2 according to CLSI 2017 standards at Cho Ray Hospital from October 2017 to March 2018. The isolates were subcultured, picked colonies, extracted DNA and perform real-time PCR with MDR-MBL kit (VIM, IMP, NDM) of Sacace (Italy) to detect the MBL class VIM, IMP and NDM.

Conclusion:
The results of this study revealved a noticeably high prevalance of MBL-producing P. aeruginosa isolates at our hospital. MBL genes among isolates which reported as sensitive to carbapenem was acting as reservoir of such resistance genes with potential risk for the silent spread of these genes in hospitals and community. So, early recognition of MBL-producing isolates, establishing efficacy infection control measures and an appropriate protocol for antibicrobial therapy based on the laboratory data are necessary to prevent the dissemination of these resistance. P. aeruginosa were first reported in Japan, and since then there have been many reports of MBLs among carbapenem-resistant P.
aeruginosa isolates in the world [4]. Mortality rates are signficantly higher in MBL producing P. aeruginosa than non-MBL P. aeruginosa [5]. Moreover, MBL can be spread from P. aeruginosa to members of Enterobacteriaceae, increasing the antimicrobial resistant rate and complication in the treatment of infected patients [6]. In addition, new antipseudomonal, such as ceftolozane-tazobactam, ceftazidime-avibactam, have better activity against MDR P. aeruginosa, however activity is just only in especially isolates with certain mechanism of resistance. Therefore, understanding the molecular characteristics of MBLs producing P. aeruginosa is very important to choose the appropriate treatment, control infection and prevent a possible global health crisis.
There are many different types of acquired MBL depending on epidemiological areas. The most important types that contribute to clinical studies are the IMP-type, VIM-type, NDM-type, SPM-type.
However, at present, there is no standard phenotypic confirmatory tests for detection MBLs among P.aeruginosa isolates. [3] Several authors show that molecular methods is the proper test for screening the presence of MBLs genes Polymerase chain reaction (PCR) has high sensitivity and reliability for detection of MBL genes among MBL-producing P. aeruginosa. At present, there is no systematic evaluation of the molecular epidemiology of MBLproducing P. aeruginosa isolates in Viet Nam. Therefore, we carry on the study to detect the features of frequencies of IMP-type, VIMtype, NDM-type genes among P. aeruginosa isolates in our hospital.

Objectives
Due to the importance of detection MBLs, in this study we determined the frequency of MBLs classifying VIM, IMP and NDM in P. aeruginosa isolates in the patients by the PCR real-time method.

Bacterial isolates
This was a cross-sectional study, in which a total of 74 non- [7] In Thailand-2019, of 153 carbapenem-resistant P. aeruginosa, this prevalence was 20.3% (31 isolates), divided into VIM-type (14 isolates) and IMP-type (17 isolates) [3]. This difference may be due to various research populations: Iran's report was focus on the burn patients, and the Thailand's report was based on the isolates from 5 regions of Thailand, our study was examined at our general hospital. This study found 29 (45.3%) isolates carried IMP-type, which was the most common MBL genes, followed by the genes NDM-type (10.9%) and VIM-type (4.7%). In 1988, transferable IMP-1 was isolated from P. aeruginosa in Japan and was found in a class 1 integrin located on a conjugational plasmid. Thereafter, it was identified in many other species suggesting horizontal gene transfer between unrelated Gram-negative species [4]. Therefore, in most studies, IMP type-producing isolates has a high prevalence. However, our result was different from a study in Iran and Thailand, that had equivalent frequency between VIM-type and IMP-type (17.5% and 15.6%) and (14 isolates and 17 isolates), respectively [8,9]. The difference may be due to the variation of geographical circulating strain.
In our present study, the NDM-type and VIM-type genes coexisted in 3 (4.7%) isolates. The genes encoding these enzymes are often located on transferable genetic platforms and can potentially spread to other species through horizontal gene transfer.
Therefore, appropriate infection control guidelines and treatment protocols are needed to prevent the further dissemination of these resistant genes to other bacterial agents in hospital.
Unfortunately, we also detected 2 (20%) MBL-producing isolates (IMP-type) in carbapenem-susceptible P. aeruginosa. This result is similar to study in Sudan, from 2015 to 2016, prevalence of MBL genes by multiplex PCR among 100 carbapenems-susceptible gram-negative clinical isolates (including P. aeruginosa) was 27 (27%) [1]. It shows that, in some cases, MBL -producing isolates express low resistance, thus we cannot use the phenotypic test to detect them. This result has the important meaning, because MBL detection by PCR assays has not been routinely performed in most of clinical microbiology laboratories. Consequently, the occurrence of MBL production in P. aeruginosa that remains susceptible to carbapenem might be unrecognized by the clinical laboratory, they can transfer the genes to other gram negative because MBLencoding genes are often carried by mobile genetic elements, increasing the antibiotic resistance rate. In addition, failing in detection MBL production among carbapenem-susceptible isolates may lead to inadequate treatment, especially in serious ill patient.

Conclusion
The results of this study revealed a noticeably high prevalence of MBL-producing P. aeruginosa isolates at our hospital, especially in some carbapenem-susceptible isolates. MBL genes among isolates which reported as sensitive to carbapenem was acting as reservoir of such resistance genes with potential risk for the silent spread of these genes in hospitals and community. Thus, early recognition of MBL-producing isolates, establishing efficacy infection control measures and an appropriate protocol for antimicrobial therapy based on the laboratory data are necessary to prevent the dissemination of these resistance.